Concurrent whole brain radiotherapy and bortezomib for brain metastasis

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Lao, Christopher D ^a   Friedman, Judah ^b   Tsien, Christina I ^c   Normolle, Daniel P ^d   Chapman, Christopher ^c   Cao, Yue ^c   Lee, Oliver ^c   Schipper, Matt ^c   Van Poznak, Catherine ^a   Hamstra, Daniel ^c   Lawrence, Theodore ^c   Hayman, James ^c   Redman, Bruce G ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bortezomib; Brain; Diffusion tensor imaging; Melanoma; MRI; Phase I; Radiation; TITE CRM

Indexed keywords

BORTEZOMIB; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; PYRAZINE DERIVATIVE;

ADULT; AGED; ARTICLE; ATAXIC APHASIA; BRAIN DISEASE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFUSION TENSOR IMAGING; DRUG DOSE ESCALATION; DRUG INDUCED DISEASE; DRUG MEGADOSE; FEMALE; HUMAN; HYPONATREMIA; MALE; NEUROIMAGING; PHASE 1 CLINICAL TRIAL; WHITE MATTER; ADVERSE EFFECTS; BRAIN; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CLINICAL TRIAL; DOSE RESPONSE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PATHOLOGY; PROCEDURES; SECONDARY; SKULL IRRADIATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; BORTEZOMIB; BRAIN; BRAIN NEOPLASMS; CHEMORADIOTHERAPY; CRANIAL IRRADIATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PYRAZINES;

EID: 84882369765     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-204     Document Type: Article

References (24)

1. Sampson JH, Carter JH, Friedman AH, Seigler HF. Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma. J Neurosurg 1998, 88:11-20. 10.3171/jns.1998.88.1.0011, 9420067.
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010, 363:711-723. 10.1056/NEJMoa1003466, 3549297, 20525992.
3. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011, 364:2507-2516. 10.1056/NEJMoa1103782, 3549296, 21639808.
4. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012, 13:459-465. 10.1016/S1470-2045(12)70090-6, 22456429.
5. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, Fariselli L, Tzuk-Shina T, Kortmann RD, Carrie C, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J Clin Oncol 2011, 29:134-141. 10.1200/JCO.2010.30.1655, 3058272, 21041710.
6. Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Margolin K, Atkins B, Thompson A, Ernstoff S, Weber J, Flaherty L, Clark I, Weiss G, Sosman J, W IIS, et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol 2002, 128:214-218. 10.1007/s00432-002-0323-8, 11935312.
7. Markovic SN, Geyer SM, Dawkins F, Sharfman W, Albertini M, Maples W, Fracasso PM, Fitch T, Lorusso P, Adjei AA, Erlichman C. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 2005, 103:2584-2589. 10.1002/cncr.21108, 15887220.
8. Pervan M, Pajonk F, Sun JR, Withers HR, McBride WH. Molecular pathways that modify tumor radiation response. Am J Clin Oncol 2001, 24:481-485. 10.1097/00000421-200110000-00013, 11586100.
9. Russo SM, Tepper JE, Baldwin AS, Liu R, Adams J, Elliott P, Cusack JC. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys 2001, 50:183-193. 10.1016/S0360-3016(01)01446-8, 11316563.
10. Normolle D, Lawrence T. Designing dose-escalation trials with late-onset toxicities using the time-to-event continual reassessment method. J Clin Oncol 2006, 24:4426-4433. 10.1200/JCO.2005.04.3844, 16983110.
11. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990, 8:1277-1280.
12. Cao Y. Development of image software tools for radiation therapy assessment. Med Phys 2005, 32:2136.
13. Chapman CH, Nazem-Zadeh M, Lee OE, Schipper MJ, Tsien CI, Lawrence TS, Cao Y. Regional variation in brain white matter diffusion index changes following chemoradiotherapy: a prospective study using tract-based spatial statistics. PLoS One 2013, 8:e57768. 10.1371/journal.pone.0057768, 3587621, 23469234.
14. Mori S, Oishi K, Jiang H, Jiang L, Li X, Akhter K, Hua K, Faria AV, Mahmood A, Woods R, et al. Stereotaxic white matter atlas based on diffusion tensor imaging in an ICBM template. Neuroimage 2008, 40:570-582. 10.1016/j.neuroimage.2007.12.035, 2478641, 18255316.
15. Mazziotta J, Toga A, Evans A, Fox P, Lancaster J, Zilles K, Woods R, Paus T, Simpson G, Pike B, et al. A probabilistic atlas and reference system for the human brain: International Consortium for Brain Mapping (ICBM). Philos Trans R Soc Lond B Biol Sci 2001, 356:1293-1322. 10.1098/rstb.2001.0915, 1088516, 11545704.
16. Wiegner EA, Daly ME, Murphy JD, Abelson J, Chapman CH, Chung M, Yu Y, Colevas AD, Kaplan MJ, Fischbein N, et al. Intensity-modulated radiotherapy for tumors of the nasal cavity and paranasal sinuses: clinical outcomes and patterns of failure. Int J Radiat Oncol Biol Phys 2012, 83:243-251. 10.1016/j.ijrobp.2011.05.044, 22019239.
17. Goel A, Dispenzieri A, Greipp PR, Witzig TE, Mesa RA, Russell SJ. PS-341-mediated selective targeting of multiple myeloma cells by synergistic increase in ionizing radiation-induced apoptosis. Exp Hematol 2005, 33:784-795. 10.1016/j.exphem.2005.04.005, 15963854.
18. Pugh TJ, Chen C, Rabinovitch R, Eckhardt SG, Rusthoven KE, Swing R, Raben D. Phase I trial of bortezomib and concurrent external beam radiation in patients with advanced solid malignancies. Int J Radiat Oncol Biol Phys 2010, 78:521-526. 10.1016/j.ijrobp.2009.07.1715, 20133082.
19. O'Neil BH, Raftery L, Calvo BF, Chakravarthy AB, Ivanova A, Myers MO, Kim HJ, Chan E, Wise PE, Caskey LS, et al. A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer. Clin Colorectal Cancer 2010, 9:119-125. 10.3816/CCC.2010.n.017, 2893386, 20378507.
20. Kubicek GJ, Werner-Wasik M, Machtay M, Mallon G, Myers T, Ramirez M, Andrews D, Curran WJ, Dicker AP. Phase I trial using proteasome inhibitor bortezomib and concurrent temozolomide and radiotherapy for central nervous system malignancies. Int J Radiat Oncol Biol Phys 2009, 74:433-439. 10.1016/j.ijrobp.2008.08.050, 2697394, 19084346.
21. Cao Y, Tsien CI, Sundgren PC, Nagesh V, Normolle D, Buchtel H, Junck L, Lawrence TS. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for prediction of radiation-induced neurocognitive dysfunction. Clin Cancer Res 2009, 15:1747-1754. 10.1158/1078-0432.CCR-08-1420, 2699596, 19223506.
22. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, Arbuckle RB, Swint JM, Shiu AS, Maor MH, Meyers CA. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009, 10:1037-1044. 10.1016/S1470-2045(09)70263-3, 19801201.
23. Jeraj R, Cao Y, Ten Haken RK, Hahn C, Marks L. Imaging for assessment of radiation-induced normal tissue effects. Int J Radiat Oncol Biol Phys 2010, 76:S140-S144. 10.1016/j.ijrobp.2009.08.077, 2843154, 20171509.
24. Chapman CH, Nagesh V, Sundgren PC, Buchtel H, Chenevert TL, Junck L, Lawrence TS, Tsien CI, Cao Y. Diffusion tensor imaging of normal-appearing white matter as biomarker for radiation-induced late delayed cognitive decline. Int J Radiat Oncol Biol Phys 2012, 82:2033-2040. 10.1016/j.ijrobp.2011.01.068, 3157581, 21570218.